It was found to enhance proliferation and resistance in lung cancer cells by targeting death receptor 5 (DR5) although through a non-exosome associated pathway (Yuan et al. 2014).
report their studies of an MCSPxDR5 bispecific, tetravalent antibody that can simultaneously target death receptor 5 (DR5, TRAIL-R2) and melanoma-associated chondroitin sulfate proteoglycan (MCSP).
Targeting death receptor activation-mediated cell death is quickly becoming one of the most promising strategies for anti-cancer therapy [3], [4].
Activated caspase-8 cleaves and activates the effector caspase-3, and activated caspase-3 cleaves target "death proteins" such as poly (ADP-ribose) polymerase (PARP) leading to apoptosis.
An alternative therapeutic option is to target death receptors such as Fas.
Targeting death receptors, such as Fas, is a promising anticancer strategy by which apoptotic cell death can be induced.
Various approaches have been described for targeting death receptor ligands to the tumors including construction of TRAIL fusion proteins using antibody fragments directed against overexpressed tumor antigens [ 11].
Another mechanism to take advantage of matrix mechanical properties therapeutically is in targeting death of cells via alterations in matrix rigidity.
Antibodies targeting death receptor 5 (DR5), a cell surface apoptosis-inducing receptor up-regulated in various types of cancer and found on HCT116 cells, were then conjugated onto the particles.
For the past two years, activists, religious minorities, intellectuals and secularist writers, among others, have been targeted for death in Bangladesh, and the deaths appear to have accelerated in recent weeks.
